title: Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
authors.affiliation: Centre Médico-Chirurgical de la Porte de Choisy, Paris.
authors.forename: J M
authors.initials: JM
authors.lastname: Brisset
authors.forename: L
authors.initials: L
authors.lastname: Boccon-Gibod
authors.forename: H
authors.initials: H
authors.lastname: Botto
authors.forename: M
authors.initials: M
authors.lastname: Camey
authors.forename: G
authors.initials: G
authors.lastname: Cariou
authors.forename: J M
authors.initials: JM
authors.lastname: Duclos
authors.forename: F
authors.initials: F
authors.lastname: Duval
authors.forename: D
authors.initials: D
authors.lastname: Gontiès
authors.forename: R
authors.initials: R
authors.lastname: Jorest
authors.forename: L
authors.initials: L
authors.lastname: Lamy
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D048289:Imidazolidines; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists; D007093:Imidazoles; D048289:Imidazolidines; C021277:nilutamide